These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29695656)

  • 1. In-Hospital Bleeding and Utility of a Maintenance Dose of Prasugrel 2.5 mg in High Bleeding Risk Patients With Acute Coronary Syndrome.
    Ohya M; Shimada T; Osakada K; Kuwayama A; Miura K; Murai R; Amano H; Kubo S; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Katoh H; Goto T; Kadota K
    Circ J; 2018 Jun; 82(7):1874-1883. PubMed ID: 29695656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
    Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
    Jeger RV; Pfisterer M; Vogt DR; Galatius S; Abildgaard U; Naber C; Alber H; Eberli F; Kurz DJ; Pedrazzini G; Vuilliomenet A; Weilenmann D; Rickli H; Hansen KW; Rickenbacher P; Conen D; Müller C; Osswald S; Gilgen N; Kaiser C
    PLoS One; 2019; 14(1):e0210821. PubMed ID: 30645635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study.
    Nakamura M; Iizuka T; Sagawa K; Abe K; Chikada S; Arai M
    Cardiovasc Interv Ther; 2018 Apr; 33(2):135-145. PubMed ID: 28213685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome.
    Chon MK; Jung SM; Lee SY; Lee SH; Hwang KW; Choi JH; Kim JS; Park YH; Kim JH; Chun KJ
    Circ J; 2020 Aug; 84(9):1582-1586. PubMed ID: 32713874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry.
    D'Ascenzo F; Grosso A; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Ali HH; Magnani G; Autelli M; Blanco PF; Garay A; Quadri G; Marra WG; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Raposeiras-Roubin S
    Int J Cardiol; 2018 Dec; 273():29-33. PubMed ID: 30228021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial.
    Koltowski L; Tomaniak M; Gross L; Rymuza B; Kowara M; Parma R; Komosa A; Klopotowski M; Jacobshagen C; Gori T; Aradi D; Huber K; Hadamitzky M; Massberg S; Lesiak M; Filipiak KJ; Witkowski A; Opolski G; Huczek Z; Sibbing D
    J Thromb Thrombolysis; 2019 Apr; 47(3):427-435. PubMed ID: 30739305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
    Savonitto S; Ferri LA; Piatti L; Grosseto D; Piovaccari G; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Rogacka R; Antonicelli R; Cesana BM; De Luca L; Ottani F; De Luca G; Piscione F; Moffa N; De Servi S;
    Circulation; 2018 Jun; 137(23):2435-2445. PubMed ID: 29459361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.
    Raposeiras-Roubín S; Caneiro Queija B; D'Ascenzo F; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Varbella F; Tomassini F; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Baz-Alonso JA; Calvo-Iglesias F; Valdés M; Cequier Á; Gaita F; Alexopoulos D; Íñiguez-Romo A; Abu-Assi E
    Rev Esp Cardiol (Engl Ed); 2019 Mar; 72(3):215-223. PubMed ID: 30029980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.